FUCA1 and cancer: Our results thus showed clearly that FUCA-1 is able to define a sub-group of luminal B, lymph node positive patients with a favorable prognosis and that this protein may represent a positive marker to discriminate a subset of LN+ patients who will have a lower risk of recurrence and longer cancer specific survival.